KOL Breakfast: Novel Treatment for AML and B-Cell Cancers, hosted by Aptose Biosciences

The meeting will feature a presentation by Industry and Key Opinion Leader, Brian Druker, M.D., who will discuss the evolution of kinase inhibitors as anticancer drugs, review the current treatment landscape in AML and B cell cancers.